ClinicalTrials.gg
RecruitingNCT06977139INSTYLEUpdated May 18, 2025

Interventional Structural Registry - LuEbeck

An observational study in Structural Heart Disease, sponsored by Prof. Dr. med. Ingo Eitel. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Prof. Dr. med. Ingo Eitel · Observational

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the registry is to investigate the effect of catheter-assisted procedures in the context of structural heart disease on clinical morbidity and mortality. Furthermore, the long-term prognosis of patients after a catheter-based procedure is to be evaluated.

In particular, the following parameters will be documented and the following questions discussed:

  • Underlying and concomitant diseases of these patients
  • Evaluation of the methods in relation to the respective disease
  • Safety - acute and long-term
  • Effectiveness - periprocedural, hospital and long-term course
  • Concomitant therapies
02

Conditions studied

  • Structural Heart Disease
03

In context

Lead sponsor

Prof. Dr. med. Ingo Eitel is the lead sponsor of 7 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients for who the indication for a catheter-based heart valve replacement or closure system was set due to a structural heart disease can be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Structural heart disease

Exclusion criteria

Exclusion Criteria:

  • Patients without consent/information
  • Age ≤ 18 years
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Combined endpoint

    Combined endpoint of NYHA classification, re-hospitalization, death, repeat procedure, heart transplantation, LVAD implantation (the order is not relevant) by day 30.

    Time frame: 30days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Jan 2030, 99 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 18, 2025
StartActual
Sep 11, 2021
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2035
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06977139
Lead sponsor
Prof. Dr. med. Ingo Eitel
Responsible party
Prof. Dr. med. Ingo Eitel (Head of Department, University of Luebeck) — Sponsor-investigator
First posted
May 18, 2025
Start date
Sep 11, 2021
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2035 (estimated)
Last update
May 18, 2025

Study contacts

Ingo Eitel, Prof. Dr.
Contact
cvro@uksh.de
+49 451 500 44501

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion